NEFM and cancer: Since NEFM DNA methylation significantly negatively correlated with TILs and many immune pathways (especially PD-L1 expression and PD-1 checkpoint pathway in cancer) in BRCA, the six CpG sites within NEFM promoter associated with poor prognosis may serve as biomarkers for predicting immune infiltration in BRCA.